Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar J, Prevoo W, Snaebjornsson P, van der Velden D, Klein M, Chalabi M, Boot H, van Leerdam M, Bloemendal HJ, Beerepoot LV, Wessels L, Cuppen E, Clevers H, Voest EE.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaay2574. doi: 10.1126/scitranslmed.aay2574.

PMID:
31597751
2.

Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.

Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, de Vos-Geelen J, Beerepoot LV, van Voorthuizen T, Creemers GJ, van Oijen MGH, van Laarhoven HWM.

Int J Cancer. 2019 Jul 24. doi: 10.1002/ijc.32580. [Epub ahead of print]

PMID:
31340065
3.

Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer.

Keikes L, de Vos-Geelen J, de Groot JWB, Punt CJA, Simkens LHJ, Trajkovic-Vidakovic M, Portielje JEA, Vos AH, Beerepoot LV, Hunting CB, Koopman M, van Oijen MGH.

Patient Educ Couns. 2019 Jul;102(7):1331-1335. doi: 10.1016/j.pec.2019.02.020. Epub 2019 Feb 22.

PMID:
30852117
4.

Efficacy of gamma knife radiosurgery in brain metastases of primary gynecological tumors.

Sadik ZHA, Beerepoot LV, Hanssens PEJ.

J Neurooncol. 2019 Apr;142(2):283-290. doi: 10.1007/s11060-019-03094-2. Epub 2019 Jan 21.

PMID:
30666465
5.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

6.

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG.

Int J Cancer. 2019 Mar 15;144(6):1453-1459. doi: 10.1002/ijc.31833. Epub 2018 Sep 24.

PMID:
30155893
7.

Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.

Rodenburg RJ, Hanssens PE, Ho VKY, Beerepoot LV.

J Neurooncol. 2018 Jun;138(2):391-399. doi: 10.1007/s11060-018-2808-6. Epub 2018 Feb 22.

PMID:
29470692
8.

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M.

Int J Clin Oncol. 2018 Jun;23(3):482-489. doi: 10.1007/s10147-017-1220-0. Epub 2017 Dec 4.

9.

Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.

Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.

Neuro Oncol. 2017 Jun 1;19(6):853-861. doi: 10.1093/neuonc/now311.

10.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
11.

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

Hermans TJ, Fransen van de Putte EE, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, de Wit R, Beerepoot LV, Verhoeven RH, van Rhijn BW.

Eur J Cancer. 2016 Dec;69:1-8. doi: 10.1016/j.ejca.2016.09.015. Epub 2016 Oct 27.

PMID:
27814469
12.

Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.

Razenberg LG, Creemers GJ, Beerepoot LV, Vos AH, van de Wouw AJ, Maas HA, Lemmens VE.

Acta Oncol. 2016 Dec;55(12):1443-1449. Epub 2016 Sep 1.

PMID:
27585122
13.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.

Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A.

Cancer. 2016 May 1;122(9):1434-43. doi: 10.1002/cncr.29864. Epub 2016 Mar 11.

14.

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.

Razenberg LG, van Gestel YR, de Hingh IH, Loosveld OJ, Vreugdenhil G, Beerepoot LV, Creemers GJ, Lemmens VE.

BMC Cancer. 2016 Feb 16;16:110. doi: 10.1186/s12885-016-2158-8.

15.

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ.

Cancer Res. 2016 Feb 1;76(3):525-34. doi: 10.1158/0008-5472.CAN-15-0776. Epub 2016 Jan 13.

16.

Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.

Hermans TJN, Fransen van de Putte EE, Horenblas S, Lemmens V, Aben K, van der Heijden MS, Beerepoot LV, Verhoeven RH, van Rhijn BWG.

Eur J Cancer. 2016 Feb;54:18-26. doi: 10.1016/j.ejca.2015.11.006. Epub 2015 Dec 18.

PMID:
26707593
17.

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A.

Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8.

PMID:
26643663
18.

Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.

Ho VK, Gijtenbeek JM, Brandsma D, Beerepoot LV, Sonke GS, van der Heiden-van der Loo M.

Eur J Cancer. 2015 Nov;51(17):2508-16. doi: 10.1016/j.ejca.2015.07.040. Epub 2015 Aug 12.

PMID:
26277099
19.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO).

Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17.

PMID:
25899986
20.

No change in lymph node positivity rate despite increased lymph node yield and improved survival in colon cancer.

van Erning FN, Crolla RM, Rutten HJ, Beerepoot LV, van Krieken JH, Lemmens VE.

Eur J Cancer. 2014 Dec;50(18):3221-9.

PMID:
25459398
21.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
22.

Patterns of metachronous metastases after curative treatment of colorectal cancer.

van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJ, Creemers GJ, Lemmens VE.

Cancer Epidemiol. 2014 Aug;38(4):448-54. doi: 10.1016/j.canep.2014.04.004. Epub 2014 May 17.

PMID:
24841870
23.

Reliability and Validity of the Psychosocial Distress Questionnaire-Breast Cancer.

Bogaarts MP, Den Oudsten BL, Roukema JA, Van Riel JM, Beerepoot LV, De Vries J.

J Nurs Meas. 2014;22(2):E14-28. doi: 10.1891/1061-3749.22.2.E14.

PMID:
26609900
24.

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM.

Clin Cancer Res. 2011 Dec 1;17(23):7337-46. doi: 10.1158/1078-0432.CCR-11-1667. Epub 2011 Oct 6. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):318.

25.

The Psychosocial Distress Questionnaire-Breast Cancer (PDQ-BC) is a useful instrument to screen psychosocial problems.

Bogaarts MP, Den Oudsten BL, Roukema JA, Van Riel JM, Beerepoot LV, De Vries J.

Support Care Cancer. 2012 Aug;20(8):1659-65. doi: 10.1007/s00520-011-1256-z. Epub 2011 Aug 24.

PMID:
21863369
26.

Development of the Psychosocial Distress Questionnaire-Breast Cancer (PDQ-BC): a breast cancer-specific screening instrument for psychosocial problems.

Bogaarts MP, Den Oudsten BL, Roukema JA, Van Riel JM, Beerepoot LV, De Vries J.

Support Care Cancer. 2011 Oct;19(10):1485-93. doi: 10.1007/s00520-010-0968-9. Epub 2010 Sep 4.

27.

A patient with subdiaphragmatic air.

Sonke GS, Beerepoot LV, Los M.

Neth J Med. 2008 Feb;66(2):89-90. No abstract available.

28.

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81.

29.

Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases.

Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, Giles RH, Voest EE.

Clin Cancer Res. 2006 Aug 15;12(16):4859-66.

30.

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE.

J Clin Oncol. 2006 Apr 1;24(10):1491-8.

PMID:
16574998
31.

Circulating endothelial cells in cancer patients do not express tissue factor.

Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HM, Voest EE.

Cancer Lett. 2004 Sep 30;213(2):241-8.

PMID:
15327840
32.

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE.

Ann Oncol. 2004 Jan;15(1):139-45.

PMID:
14679134
33.

Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.

Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE.

Clin Cancer Res. 2003 Sep 15;9(11):4025-33.

34.

Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.

Crul M, Beerepoot LV, Stokvis E, Vermaat JS, Rosing H, Beijnen JH, Voest EE, Schellens JH.

Cancer Chemother Pharmacol. 2002 Dec;50(6):473-8. Epub 2002 Oct 25.

PMID:
12451474
35.

Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP.

J Clin Invest. 1996 Oct 1;98(7):1667-75.

36.

Up-regulation of vascular endothelial growth factor production by iron chelators.

Beerepoot LV, Shima DT, Kuroki M, Yeo KT, Voest EE.

Cancer Res. 1996 Aug 15;56(16):3747-51.

Supplemental Content

Loading ...
Support Center